You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

Galantamine hydrobromide - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for galantamine hydrobromide and what is the scope of freedom to operate?

Galantamine hydrobromide is the generic ingredient in three branded drugs marketed by Aurobindo Pharma, Barr, Impax Labs, Norvium Bioscience, Sun Pharm, Watson Labs, Janssen Pharms, Hikma, Apotex Inc, Aurobindo Pharma Ltd, Chartwell Rx, Dr Reddys Labs Ltd, Heritage Pharma, Mylan, Sandoz, Yabao Pharm, and Zydus Pharms Usa Inc, and is included in twenty-two NDAs. Additional information is available in the individual branded drug profile pages.

There are twelve drug master file entries for galantamine hydrobromide. Thirteen suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for galantamine hydrobromide
Drug Prices for galantamine hydrobromide

See drug prices for galantamine hydrobromide

Recent Clinical Trials for galantamine hydrobromide

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Vanderbilt University Medical CenterPhase 1
Duke UniversityPhase 4
Ortho-McNeil Neurologics, Inc.Phase 4

See all galantamine hydrobromide clinical trials

Generic filers with tentative approvals for GALANTAMINE HYDROBROMIDE
Applicant Application No. Strength Dosage Form
⤷  Sign Up⤷  Sign Up12MGTABLET; ORAL
⤷  Sign Up⤷  Sign Up8MGTABLET; ORAL
⤷  Sign Up⤷  Sign Up4MGTABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for galantamine hydrobromide
Medical Subject Heading (MeSH) Categories for galantamine hydrobromide
Anatomical Therapeutic Chemical (ATC) Classes for galantamine hydrobromide
Paragraph IV (Patent) Challenges for GALANTAMINE HYDROBROMIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
RAZADYNE ER Extended-release Capsules galantamine hydrobromide 16 mg and 24 mg 021615 1 2006-03-11
RAZADYNE ER Extended-release Capsules galantamine hydrobromide 8 mg 021615 1 2006-03-02
RAZADYNE Tablets galantamine hydrobromide 4 mg, 8 mg and 12 mg 021169 14 2005-02-28

US Patents and Regulatory Information for galantamine hydrobromide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm GALANTAMINE HYDROBROMIDE galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 090178-002 Feb 2, 2011 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Watson Labs GALANTAMINE HYDROBROMIDE galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 079028-001 Dec 15, 2008 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Chartwell Rx GALANTAMINE HYDROBROMIDE galantamine hydrobromide TABLET;ORAL 077587-001 Jul 9, 2009 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for galantamine hydrobromide

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms RAZADYNE ER galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 021615-002 Apr 1, 2005 ⤷  Sign Up ⤷  Sign Up
Janssen Pharms RAZADYNE galantamine hydrobromide TABLET;ORAL 021169-002 Feb 28, 2001 ⤷  Sign Up ⤷  Sign Up
Janssen Pharms RAZADYNE ER galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 021615-001 Apr 1, 2005 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.